Highlights Geron Corporation

Equities

GERN

US3741631036

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2024 BST			5-day change	1st Jan Change
3.81 ^USD	-1.55%		-6.62%	+80.57%

05-03	Wedbush Adjusts Geron's Price Target to $7 From $6, Keeps Outperform Rating	MT
05-02	Geron Shares Decline After Q1 Loss Widens	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Geron Shares Decline After Q1 Loss Widens	05-02	MT
Geron Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
North American Morning Briefing : Traders Wait for -2-	05-01	DJ
Geron Prices $150 Million Offering of Shares, Pre-Funded Warrants	03-19	MT
Geron Shares Soar on Positive FDA Advisory Panel's Vote on Imetelstat for Blood Disorder	03-15	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday as Rate Cut Hopes Wane	03-15	MT
Geron Gets Favorable Vote From FDA Advisory Committee on Imetelstat for Blood Disorder	03-14	MT
Geron Corporation Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS	03-14	CI
Geron's blood disorder drug gets FDA advisers' backing	03-14	RE
Geron's Imetelstat's Safety a Key Focus for FDA's Oncology Drugs Advisory Committee Meeting; Shares Slump	03-12	MT
Geron's Imetelstat's Safety a Key Focus for FDA's Oncology Drugs Advisory Committee Meeting	03-12	MT
US FDA staff flags concerns about Geron's anemia treatment	03-12	RE
Geron's Q4 Net Loss Narrows, Revenue Declines	02-28	MT
Geron Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Geron Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Geron Announces 50% Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis	12-06	CI
Geron Announces Publication in the Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS	12-04	CI
Geron Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Geron Says EU Drug Watchdog Validates Imetelstat's Marketing Authorization Application	29/09/23	MT
EARNINGS: R&Q Insurance loss swells, Jade Road still selling assets	29/09/23	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Geron Corporation

Equities

GERN

US3741631036

Highlights

Filters